3M5M

avoiding drug resistance against hcv ns3/4a protease inhibitors

• Total interactions analyzed: 3
• Total true interactions: 2
• Strongest Interaction:
  • Chains: B-C
  • Int. Res.: 47
  • Norm. En. per Res.: -6.972
• Hub Node: A(1)

All Interactions

Chains	Hydro. Bond Ener. (kJ/mol)	Elec. Ener. (kJ/mol)	VDW. Ener. (kJ/mol)	Tot. Stab. Ener. (kJ/mol)	#int. res.	# Short cont.	#Hydr. int.	#VDW pairs	#salt bridges	#Pot. fav. elec. int	#Pot. unfav. elec. int
A-B	-13.3066	16.5491	-57.7495	-54.507	38	2	0	1841	0	14	8
B-C	-105.0247	-41.3078	-181.351	-327.6835	47	10	0	5237	2	23	7

Interface residues

• A-B: ALA1147B, ALA984A, ARG1024A, ARG1118B, ARG1123B, ASP1103B, ASP1121B, CYS1097B, CYS1099B, CYS1145B, GLN1017A, GLN1021A, GLU1013A, GLU1014A, GLU1018A, GLU1173B, GLY1015A, GLY1023A, GLY1100B, GLY1120B, LEU1104B, LYS1080B, LYS987A, LYS988A, MET986A, PRO1146B, PRO1171B, SER1020A, SER1101B, SER1102B, SER1122B, SER1174B, SER985A, THR1019A, THR1022A, THR1098B, THR1177B, TYR1105B
• B-C: ALA1139B, ALA1156B, ALA1157B, ALA1164B, ALA1166B, ARG1109B, ARG1123B, ARG1155B, ARG1161B, ASP1081B, ASP1168B, ASP2C, CYS7C, GLN1041B, GLU3C, GLU5C, GLU6C, GLY1058B, GLY1124B, GLY1137B, GLY1140B, GLY1141B, GLY1162B, HIS1057B, ILE1132B, LEU1044B, LEU1106B, LEU1135B, LYS1136B, LYS1165B, MET4C, PHE1043B, PHE1154B, PHE1169B, PHE1C, SER1122B, SER1133B, SER1138B, SER1159B, THR1042B, THR1108B, THR1160B, TYR1134B, VAL1055B, VAL1158B, VAL1163B, VAL1167B